T1	Condition 23 31	dementia
T2	Qualifier 48 55	serious
T3	Qualifier 60 68	unstable
T4	Scope 48 68	serious and unstable
T5	Condition 97 104	hepatic
T6	Condition 106 111	renal
T7	Condition 113 130	gastroenterologic
T8	Condition 132 143	respiratory
T9	Condition 145 159	cardiovascular
T10	Condition 241 251	neurologic
T11	Condition 225 239	endocrinologic
*	OR T5 T6 T7 T8 T9 T11 T10
T12	Condition 171 193	ischemic heart disease
T13	Condition 198 222	congestive heart failure
*	OR T12 T13
T14	Condition 263 269	stroke
T15	Condition 271 296	transient ischemic attack
T16	Condition 298 321	subarachnoidal bleeding
T17	Condition 323 334	brain tumor
T18	Condition 336 350	encephalopathy
T19	Condition 356 366	meningitis
*	OR T14 T15 T16 T17 T18 T19
T20	Scope 263 366	stroke, transient ischemic attack, subarachnoidal bleeding, brain tumor, encephalopathy, and meningitis
R1	Subsumes Arg1:T10 Arg2:T20	
T21	Scope 171 223	ischemic heart disease and congestive heart failure)
R2	Subsumes Arg1:T9 Arg2:T21	
T22	Scope 97 366	hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease and congestive heart failure), endocrinologic, neurologic (including stroke, transient ischemic attack, subarachnoidal bleeding, brain tumor, encephalopathy, and meningitis
R3	Has_scope Arg1:T22 Arg2:T4	
T23	Condition 397 415	allergic reactions
T24	Drug 419 427	loxapine
T25	Drug 431 440	amoxapine
*	OR T24 T25
T26	Scope 419 440	loxapine or amoxapine
R4	Has_scope Arg1:T23 Arg2:T26	
T27	Competing_trial 442 563	Patients who have received an investigational drug within 30 days prior to the current agitation episode must be excluded
T28	Post-eligibility 566 684	Patients who are considered by the investigator, for any reason, to be unable to self-administer the inhalation device
